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1. Background and scope of thesis
1.1. Necessity of vaccine adjuvant development
In 2005, 7.6 million people died by cancer out of 58 million deaths worldwide.1, 2 Based
on projections, cancer deaths will continue to increase with an estimated 9 million people
dying from cancer in 2015, and 11.4 million in 2030 (World Health Organization, 2006a).
Cancer can be treated by surgery, chemotherapy, radiation therapy and immunotherapy.3, 4
Complete elimination of the tumor without damage to the rest of the body would be the ideal
aim of treatment. Sometimes this can be achieved by tumor tissue surgery, but the propensity
of cancers to spread adjacent tissue by microscopic metastasis often limits its effectiveness.
There are side effects associated with chemotherapy and radiotherapy that can have a
negative effect on normal cells near the cancer. On the other hand, Immunotherapy has great
potential to treat cancer and prevent future relapse by triggering the immune system to
recognize and kill cancer cells. A variety of strategies are continuing to evolve in the
laboratory and in the clinic, including therapeutic non-cellular (vector-based or subunit)
cancer vaccines4, dendritic cell vaccines5, 6, engineered T cells7-9, and immune checkpoint
blockade10-12. Despite their promising approaches, much more research is needed to address
problems in immunology such as how and why certain cancers fail to respond to
immunotherapy. The newly emerging field of immune-engineering is exploring some of
these challenges, and there is ample opportunities for engineers to contribute their ideas and
tools to mediate cancer regression in preclinical and clinical models.13, 14
To understand how immunotherapy works, it is necessary to know how the immune system
protects our body against disease. Vertebrates are emerged with two complementary immune
systems, the innate immune system and the adaptive immune system.15 The adaptive immune
system is equipped with two key weapons: antigen-recognizing lymphocytes, B cells and T
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cells, which specifically target the invader, and provide a memory response to prevent a
repeat of the infection.16, 17 The innate immune system, in contrast to the adaptive system, is
the first defense line, eliciting inflammatory response at the early stage.18 To protect the host
from succumbing to infections, the innate immune system phagocytoses the pathogen,
recruits natural killer cells (NK cells), and maturates dendritic cells. Those innate immune
responses are linked to adaptive immune responses following four fundamental tasks. First,
innate immune system must rapidly detect any infectious agent, regardless of whether it is a
fungus, virus, bacteria, or parasite. Second, innate immune cells need to rapidly categorize
the type of invading infectious agent. Third, innate immune defenses eliminate the pathogen
or internalize the categorized infectious agents. Fourth, innate immune cells induce the
appropriate type of adaptive immune response, thereby eradicating the infection and
preventing its recurrence.
The primitive part of innate immune cells that enables them to recognize conserved
pathogen seems to be their repertoire of what have been termed pattern-recognition receptors
(PRRs), which lead to transcriptional expression of inflammatory mediators that coordinate
the elimination of pathogens.19 The toll-like receptor (TLR) is one of the best-characterized
PRR families and 10 types of TLR are known in humans.20 TLRs that are responsible for
sensing molecule’s characteristic of extracellular pathogens are expressed on cell surface,
whereas TLRs that detect intracellular pathogens are expressed within innate immune cells.
For example, TLR9 detects unmethylated CpG dinucleotides, which are relatively common
in bacterial DNA.21, 22
Most types of immune cells do not express TLR9, and thus are not activated directly by
CpG oligonucletodes (ODNs). CpG ODNs only activate cells expressing TLR9 receptors. In
mice, plasmacytoid dendritic cells (pDCs) activated through TLR9 create a TH1-like cytokine
milieu by secreting INF-α/β, IL-12, TNF-α. These cytokines are considered to be important
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in triggering TH1 responses, which may explain why administration of mice with this TLR9
ligand gives a higher level of antigen-specific IFN-γ secretion and CD8+ T cells.13 CpG
ODNs enhance the number and function of tumor-specific cytotoxic CD8+ T cells.23 The
TH1-like cytokine milieu also activate NK cells, secreting IFN-γ and gaining lytic activity. In
addition, the B cells turn to more sensitive to activation through their antigen receptor, and
both B cells and pDCs can trigger expression of costimulatory molecules, enhancing their
ability to activate T cell responses.15 All of the cellular immune effects of CpG ODNs are
thought to result from TLR9- stimulated B cells and pDCs, showing expression of costimulatory molecules and co-activation of naive T cells and germinal center or memory B
cells through their antigen receptor (Figure 1-1).24

Figure 1-1. CpG cellular mechanism of action.

CpG ODNs are easy to synthesize in the lab and are used as vaccine adjuvants to augment
the immune responses (Figure 1-1). To avoid the rapid enzymatic degradation in vivo, CpG
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ODNs are most often made with a nuclease-resistant phosphorothioate backbone. They are
effective for preventing and treating infectious diseases, allergies, and cancers by activating
host defense mechanisms which elicit innate and acquired immune responses.25 Thus, CpG
ODNs have been widely used as an effective therapeutic tool to enhance immune responses
through the activation of TLR9. However, parenteral administration of unformulated CpG
ODNs fails to reach lymph nodes (LNs), the anatomic organ where the primary functions of
immune cells are orchestrated. LNs are highly organized structures where the interaction
among T cells, B cells, and APCs are hosted in a stromal cell matrix. They are thus central
targets in antigen presentation and immune activation.26 Adjuvants fail to reach the LNs often
lead to unacceptable systemic side effects, which have limited the advance of adjuvants in
vaccine applications. Thus, approaches that target vaccine components to LNs play key
roles in promoting immune activation and have the great potential in transforming disease
treatment.
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1.2. Scope and outline of thesis
In this thesis, we introduced therapeutic applications of activating TLR9 with synthetic
CpG oligodeoxynucleotide (ODN) agonists in nanoparticle or molecular form to activate
immune responses in animal models. As a nanoparticle deliver platform, positively charged
silica nanoparticles (SiNPs) were explored to load immunomodulators that are capable of
targeting the draining LNs (dLNs) and mimicking the size, geometry and surface feathers of
live viral pathogens. We next demonstrated the use of microneedles arrays as a transdermal
delivery platform prepared by a water-soluble polymer to release molecular vaccines in
epidermis and target them to draining lymph nodes.
Chapter 2 describes lipid coated SiNPs for targeting CpG DNA to dLNs. Immunization
with nanoparticles showed potent cellular and humoral immunity superior to vaccination
with soluble CpG ODNs. We systematically characterized electrostatic charge interactions
between SiNPs and CpG ODNs, and explored the optimum loading ratio of CpG ODNs on
SiNPs, which lead to high colloidal stability with enhanced lymphatic uptakes. We then
compared immunogenicity profiles of nanoparticle and soluble CpG ODN in vaccination.
In Chapter 3 we explored the transdermal delivery platform using dissolving microneedle
arrays (MNs), which can penetrate the skin and facilitate the rapid release of vaccine
components in epidermis. We combined this strategy with an albumin ‘hitchhiking’ approach
that can promote interaction with and uptake across the lymphatic endothelium. Vaccination
via MNs generated robust immune responses, showing enhanced T cell and antibody
responses. We characterized the morphology and vaccine loading capabilities of MNs, and
systematically explored how the transdermal delivery of molecular vaccines impacted
cellular and humoral immunities.
Chapter 4 is the conclusion and future work.
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2. Lipid coated silica nanoparticles as a pathogen mimicking platform for
lymph node targeting

2.1. Introduction
Vaccination is to stimulate the immune system by administration of antigenic materials
in order to develop adaptive immunity to diseases. It represents the single most effective
medical intervention in modern medicine. Traditionally, attenuated live or killed whole
pathogens were administrated into human body to trigger protective immune responses
without causing illness. Recent advances in immunology have led to the development of
more defined synthetic subunit antigens (proteins, peptides or nucleic acids) to improve
vaccine stability, safety and tolerability. More importantly, subunit vaccines are able to elicit
selective immunity to a particular antigen, avoiding activation of unrelated immunity.
Subunit vaccines have received great enthusiasm in attempt to develop vaccines for chronic
infectious diseases such as HIV and cancer, where cytotoxic CD8+ T cells responses are
needed. Unfortunately, subunit vaccines are usually poorly immunogenic and require coadministration of adjuvants and/or delivery carrier to generate an effective immune response.
Synthetic particulate delivery systems combined with immunological cues which mimic the
natural pathogens are of particular interest in vaccine applications. In the past three decades
numerous delivery systems based on nano- or micro-sized particles have been investigated
preclinically and technologies have already been introduced to the clinic. Particle-based
delivery systems have significant advantages over their nonformulated counterparts. For
example, nanoparticles can protect antigen from degradation, co-deliver antigen and immune
stimulatory signals, and enhance antigen uptake by targeting the immune system.27-30 It has
been demonstrated that the cell-mimicking approach enables cellular endocytotic pathways
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to be optimized in the lysosomes entry to uptake nanoscale particles31-34, and the resulting
biomimetic nanoparticles have been used for various biomedical functions, including
bioscavenger applications for toxin neutralization35, 36 and antibacterial vaccine strategy for
immunomodulation37-40. Previous studies also showed biomimetic nanoparticles containing
both tumor-specific antigen and adjuvant generated strong antigen specific immune
responses41 and potent anti-tumor efficacy.42, 43
Despite intensive research, only a few of the particulate system reach clinical trials and
the results are rather disappointing, especially for cancer vaccines. This highlights the needs
for new system which can efficiently target vaccine components to antigen presenting cells
(APCs) and elicit the desired immune responses. An important mechanism underlying the
use of nanomaterials in vaccine is that of functional mimicry of natural pathogens.
Nanoparticles mimic the size, charge and surface features of pathogens and preferably
captured by immune cells. Here we describe a lipid-coated silica nanoparticle (SiNPs)
delivery system which can efficiently accumulate in the draining lymph nodes after injection.
We hypothesize that immune signal decorated SiNPs, with optimized sizes (5-100 nm
diameters), are capable of targeting the draining LNs (dLNs) and mimicking the size,
geometry and surface features of live viral pathogens. After subcutaneous injection, these
nanoparticles can accumulate in LNs, where a large portion of immune cells reside. We show
that cationic silica nanoparticles can be efficiently loaded with CpG oligonucleotide adjuvant.
Subsequent lipid coating on these nanoparticles not only improves their stability, but also
markedly reduces the non-specific tissue interaction after injection. Immunization with lipidcoated silica nanoparticles potentiates the in vivo generation of antigen-specific cytotoxic T
cells and antibody response, which in turn, lead to enhanced anti-tumor efficacy. Our
findings provide a simple, efficient and safe method to target molecular therapeutics to LN
to modulate the immune system.
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2.2. Materials and methods
2.2.1. Preparation of CpG ODN loaded SiNPs (CS) and lipid-coated SiNPs (LCS)
SiNPs were purchased from Sigma Aldrich that were initially functionalized by
triethoxypropylaminosilane (density: 1.158 g/mL). Lipids were purchased from Avanti Polar
Lipids except mPEG-DSPE (from Laysan Bio). The size of SiNPs was less than 30 nm and
was confirmed by dynamic light scattering (DLS) measurements (Malvern Zetasizer). The
SiNPs solution was diluted 10 times using D.I. water to decrease the nanoparticle density
(0.116 g/mL) and added to desired amount of CpG to prepare CpG-loaded SiNPs with
different weight ratios (SiNPs/CpG) such as 10, 30, 60, 90, and 150. The probe-sonication
was performed for 1 min with 2/2s on/off working cycle at a power output of 4 joules. During
encapsulation, CpG was fixed onto positively charged SiNPs and was subsequently coated
with

lipid.

To

coat

the

SiNPs

with

lipid

bilayer,

a

mixed

lipids

(cholesterol/DOPC/DSPE/mPEG-DSPE at molar ratio of 31.5:45:13.5:10) were used. Lipids
mixture were first suspended in chloroform and the solvent was evaporated to form a lipid
film. These films were then placed in a chemical hood connected to a vacuum chamber over
night to remove trace amounts of organic solvent impurities. Following the addition of the 1
mL of particle suspension to the coated lipid film, probe-sonication was performed for 20
min with 15/15s on/off working cycle at a power output of 4 joules. Since the suspension
contained coated particles and can be separated by centrifugation, free liposomes were
removed by centrifugation at 15,000 rpm for 10 min, followed by washing three times in
saline.
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2.2.2. Size and zeta potential measurements
To measure the size and zeta potential of nanoparticles, Dynamic light scattering (DLS,
Zetasizer, Malvern) was used with He-Ne laser (633 nm) at 90° collecting optics at 25 °C.
The measurements were performed with the nanoparticles suspended in saline. The surface
morphology and microstructures were analyzed using a high-resolution transmission electron
microscopy (HR-TEM, JEOL 2010). For TEM analysis, microfilms were made by placing a
drop of the respective nanoparticle suspensions onto a 200 mesh copper TEM grid (Ted Pella,
CA) and then dried at room temperature for 3 h. To visualize the lipid bilayer on nanoparticles,
2 % phosphotungstic acid (1:1 v/v) was used for negative staining. A minimum of four
images for each sample was captured, and representative images were included in Figure 27.

2.2.3. In vitro characterization
HEK-Blue™-mTLR9 cells were purchased from InvivoGen and were used to evaluate
adjuvant activity in vitro. The cells were cultured in RPMI (Thermo Fisher), containing 10 %
FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2mM L-glutamine. Inducible SEAP
(Secreted Embryonic Alkaline Phosphatase) level were detected by HEK-Blue™ detection
kit from Invivogen. Mice TLR9 (mTLR9) cells were cultured in an incubator at 37 °C and
then were transferred into a 96-well plate. Nanoparticles or soluble CpG were added to per
well of 96-well plate and after 24 h incubation, the stimulation of mTLR9 cells was assessed
by measuring the levels of SEAP secretion using QUANTI-BlueTM quantitatively measured
by a spectrophotometer at 645 nm.
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2.2.4. Analysis of cellular uptake
DC 2.4 cells were kindly provided by Dr. Wei (Barbara Ann Karmanos Cancer Institute,
Detroit, MI). To determine the intracellular delivery capacity of nanoparticles, the DC2.4
cells were seeded on glass coverslips in 6-well microscopy chamber at a density of 2 x 104
cells per well for 24 h at 37 °C. After 24 h, cells were treated with 10 μg/ml of fluorescence
labeled CpG in soluble or in nanoparticle form for 2 h, and then washed with saline. For
fixation, the glass that cells adhered on was immersed in 4 % paraformaldehyde in saline for
10 min at room temperature. Following fixation, the glass was washed with saline and
mounted on a slide with nuclei staining by DAPI. Fluorescence images were obtained using
a confocal microscope (Zeiss LSM 510) with a filter set of DAPI and FITC
excitation/emission. For the FACS analysis, DC2.4 cells were seeded on 6-well plates at a
density of 4.5 x 105 cells/well in the culture medium. Fluorescently labelled CpG in soluble
or in nanoparticle form were added to each well and incubated for 0.5 h, 1h, and 2 h,
respectively. After washing with saline, the cells were analyzed using a flow cytometer
(Attune Focus). A minimum of 100 events were collected.

2.2.5. In vivo lymph node targeting
All animal studies were approved by the division of laboratory animal resources (DLAR)
and animals were cared in the DLAR animal facility under federal, state, local, and NIH
guidelines for animal care. Groups of C57BL/6 (n=2) were injected subcutaneously with 3
nmol of fluorescein-labelled CpG in soluble or in nanoparticle formulations. After 24 h or 30
h, LNs were digested with 1.5 mL of freshly prepared enzyme mix comprised of RPMI-1640
containing 0.8 mg/mL Collagenase/Dispase (Roche Diagnostics) and 0.1 mg/mL DNase
(Roche Diagnostics) and LN cells were stained with antibodies against F4/80 and CD11c

１１

versus CpG fluorescence in viable cells. Percentages of CpG+ cells in the LNs were
determined by flow cytometry at 24 h or 30 h.

2.2.6. Immunization
Groups of C57BL/6 mice (n=3 per group) were immunized by subcutaneous injection on
day 0 and day 14 with 10 μg ovalbumin (OVA) or 10 μg DSPE-PEG-OVA-II (amph-OVAII) plus CpG in soluble or in nanoparticle based adjuvants. Seven day after the final
immunization (day 21), mice were bled and peripheral blood mononuclear cells were
evaluated by SIINFEKL/H-2Kb peptide-MHC tetramers staining and intracellular cytokine
(IFN-gamma and TNF alpha) staining. To assess the functionality of primed CD8+ T cells,
peripheral blood mononuclear cells were stimulated ex vivo with 10 μg/mL OVA peptide
SIINFEKL for 6 h with Brefeldin-A, fixed, permeabilized, stained with anti-IFN-γ, antiTNF-α, and anti-CD8α, and analyzed by flow cytometry. Anti-OVA IgG titers, defined as the
dilution of serum at which 450 nm OD were determined by an enzyme-linked
immunosorbent assay (ELISA) analysis. To determine antibody titers, ELISA plates
(eBioscience) were coated with 10 μg/mL of OVA in saline overnight at room temperature.
The plates were blocked with 200 μL of 1% bovine serum albumin (BSA) in saline for 1 h.
Serum was serially diluted in saline between 1:102 and 1:107, and applied to the plate and
incubated for 1 h at room temperature. Peroxidase-conjugated goat anti-mouse IgG (HþL)
(1:5000 in 1% BSA-PBST, 100 μL/well) was then applied for 1 h, and the plates were
developed using TMB substrate (100 μL/well, eBioscience). The reaction was stopped using
50 μL of 1 M sulfuric acid and absorbance values were measured at 450 nm. Interlukin (IL)6 and IL12 were also analyzed using cytokine-specific ELISA (BD Biosciences) according
to the manufacturer’s instructions.
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2.2.7. Tumor model
EG.7-OVA cells (Mouse thymoma EL4 cells) were purchased from ATCC and 2 x 106 cells
were subcutaneously inoculated into the right flank of 5-6-week-old C57BL/6 mice. When
the tumor mass became palpable (7-8 mm, typically 5 days later), mice were divided into
five treatment groups (n=6) and the tumor-bearing mice were subcutaneously injected with
20 μg OVA or 20 μg amph-OVA-II plus 1.24 nmol CpG in nanoparticle form. Survival and
tumor size were measured everyday using a sliding caliper. The tumor volume was calculated
using the following formula: tumor volume (mm3) = length x (width)2/2.44

2.2.8. Statistical analysis
To analyze the statistical difference between groups, a one-way analysis of variance
(ANOVA) with Tukey’s HSD post-hoc test was used. All of the values are expressed as
means ± standard deviations. GraphPad Prism software was used for all the statistical
analyses. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. NS, not significant.

2.3. Results and discussion
2.3.1. Design of LN-targeting CpG loaded SiNPs
A major obstacle in subunit vaccines is the insufficient delivery of the vaccine components
to the lymph nodes. Vaccine delivery by nanocarriers could make a big impact on the
treatment of infectious diseases as well as on cancer immunotherapy. Properties of nanosized vaccine carrier are highly tunable. For example, surface of nanocarriers can be easily
modified to expose either antigen or adjuvant (or both), allowing co-delivery of antigen and
immune signal to LNs, which result in greater lymphocyte priming. In this respect, porous
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nanoparticles such as mesoporous SiNPs45 or nanoporous polymer-based spheres46 have been
employed with some success for vaccine delivery. However, extra steps are needed to
fabricate the templates, which involve complex chemical and physical process occurring at
several times. It is also costly for the fabrication of large-scale mesoporous SiNPs with
controlled pore orientations.47-49 In addition, the vaccine encapsulation efficiency and the
bioaccessibility of loaded vaccine also need to be addressed in more detail.45 Although drug
delivery systems via nanoparticles50-54 has been gaining momentum in the past decade, the
development of simple and efficient delivery vehicles for in vivo applications, especially for
delivery to LNs, has remained a major challenge.
To prepare the pathogen mimicking SiNPs with stimulatory DNA encapsulated, we choose
a cationic silica nanoparticle. Cationic nanoparticles have been widely used to condense
DNA in transfection. Briefly, amine modified SiNPs (30 nm) were complexed with CpG
DNA, a single-stranded synthetic oligodeoxynucleotides with cytosine-phosphate-guanine
motifs that can activate the APCs expressing the pathogen recognition receptor Toll-like
receptor 9 (TLR9). We first prepared fluorescein amidite (FAM)-labelled CpG-loaded SiNPs
(CS) with different weight ratios (SiNPs/CpG) of 10, 30, 60, 90, and 150 to find the optimum
loading ratio of CpG DNA on SiNPs, focusing on the nanoparticle’s stability (Figure 2-1a
and b). The desired amount of SiNPs were simply added to fluorescence labelled CpG
solution and briefly probe-sonicated, following 1 h incubation at room temperature (figure
2-1c). 10, 30, 60, and 90 ratio CS showed a precipitated layer on the bottom of 1.5 mL
microcentrifuge tubes, emitting green fluorescence under the UV lamp, implying that the
interaction between SiNPs and CpG DNA was sufficient to promote significant aggregation
of nanoparticles (defined here as formation of clusters of three or more nanoparticles). In
contrast, soluble 3’-FAM CpG DNA and 150 ratio CS showed uniform green fluorescence,
indicating a formation of stabilized NPs.To further confirm their soluble stability, brief
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centrifugation (5,000 rpm for 5 s) was performed for all samples and 150 ratio CS showed
excellent solution stability (no precipitate layer) that was similar to soluble 3’-FAM CpG
DNA (Figure 2-1d). To quantify the amount of CpG DNA absorbed onto the SiNPs surface,
the supernatant after centrifugation was analyzed by UV-vis measurement (Figure 2-1e). The
amount of CpG DNA in the supernatant decreased with increasing the SiNPs/CpG weight
ratio from 10 up to 60, but it was increased when the surface coverage of CpG DNA on SiNPs
was reduced (90 and 150 ratio CS). Those two 90 and 150 ratio CS showed a characteristic
DNA adsorption curves under the UV region, which also were slightly lifted up compared to
other curves, indicating detected CpG DNA from 90 and 150 ratio CS were originated from
the surface of SiNPs, not from soluble CpG DNA. In particular, 150 ratio CS showed the
equivalently same level of peak intensity measured from soluble CpG DNA, indicating 150
ratio CS was uniformly distributed in the solution. The saturation point was found at 60 ratio
CS, representing the loss of CpG DNA from SiNPs was less than 5 %. At this ratio, SiNPs
were expected to be fully covered by CpG DNA, enabling high loading of CpG DNA per
nanoparticle, but 150 ratio CS looked more reasonable for vaccine delivery in terms of their
colloidal stability. The 150 ratio CS was relatively stable in serum, releasing 20 % of the
adsorbed CpG DNA when incubated in the presence of 10 % serum at 37 oC for 3 days
(Figure 2-1g).
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Figure 2-1. a) Illustration of FAM CpG-SiNPs preparation based on their charge interactions.
b) Table showing CS with their different weight ratios in the study. c) Fluorescent image
showing CS samples after incubation at room temperature for 1 h. d) Image showing CS
samples after brief centrifugation (5000 rpm for 5 second). e) UV-vis absorbance from the
supernatant of CS samples. f) FAM CpG concentration measured from the supernatant of CS
samples. g) Kinetics of FAM CpG DNA release from nanoparticles incubated in saline
containing 10 % serum at 37 oC.
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Motivated by above findings, the aggregation of nanoparticles was ascertained by DLS
measurements. In view of the results shown in Figure 2-2a, the size of CS decreased with
increasing SiNPs/CpG DNA weight ratio, indicating their aggregation was more significant
when SiNPs were fully covered by CpG DNA. Only 150 ratio CS showed monodisperse in
size (45 nm) and uniform in loading, two features of utmost importance for reliable adjuvant
dosage. The results from zeta-potential measurements showed a positively charged surface
feature from bare SiNPs, which reflects strong electrostatic interactions with negatively
charged CpG ODN (Figure 2-2b). The surface saturation point shown in Figure 2-1f was
corroborated by zeta-potential measurements, which showed a progressive decrease in
surface potential from 31 mV for SiNPs to 4 mV for the 60 ratio CS. Since the 10, 30, 60,
and 90 ratio CS gave very large aggregates, the 150 ratio CS was selected for further vaccine
studies. The potential profiles in the stern layer and the diffusion layer are illustrated in Figure
2c based on potential in SiNPs. The 150 ratio CS covered partially by CpG DNA has
positively charged surface (~15 mV) and creates an electrostatic field that affects the ions in
the bulk of the liquid, thereby creating an electric double layer. Thus it can be said that
particles tend to segregate into a layer adjacent to the layer of surface charges in SiNPs,
showing better colloidal stability of nanoparticles.
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Figure 2-2. a) NPs size by volume. b) NPs zeta potential. c) Expected distance between two
CS particles with low and high weight ratio, and its expected distance of diffusion layer.

2.3.2. SiNPs formulation efficiently targets CpG to the LN.
It is well known that the parenteral administration of unformulated CpG DNA fails to
reach lymph nodes (LNs), the anatomic organ where the primary function of immune cells
is orchestrated. Thus, efficient LN-targeting strategy has the key roles in promoting immune
activation and has the great potential to transform disease treatment. To see whether 150 ratio
CS reflect sufficient transport of CpG DNA to dLNs, we assessed LN accumulation following
subcutaneous injection, using a fluorophore-conjugated derivative to enable detection of
CpG in the tissue (Figure 2-3a). The CS with different weight ratios were injected in
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C57BL/6 mice (n = 2 per group), and 24 h later, dLNs were excised (Figure 2-3b). The LNs
from mice injected with 60, 90, and 150 ratio CS showed bigger inguinal or axillary LNs
than LNs from mice injected with soluble CpG DNA or saline (Figure 2-3c). On the other
hand, mice injected with 180 ratio CS showed swelling at the injection site and it last one
week from the day of administration (Figure 2-3d). By injecting 300 ratio CS into mice,
inflammation occurred in response to redness and tissue damage. Strongly cationic particles
are known to be toxic and to interact more favorably with the tissue thereby inducing
inflammation.55, 56 However, in contrast to the results above, mice injected with 150 ratio CS
showed a semblance of normality. By flow cytometry, 30, 60, and 180 ratio CS exhibited low
accumulation in CD11c+ DCs or F4/80+ macrophage, whereas 150 ratio SiNPs showed
marginally increased uptake in inguinal or axillary LNs (Figure 2-3e, f, and g). This results
implies that 150 ratio CS has a reasonable fit of surface charge that can enhance delivery of
CpG DNA to lymphatics and promote their capture in dLNs without any inflammations at
the injection site. Inefficient capture of CpG DNA in LNs is consistent with the low molecular
weight of soluble CpG DNA, big size of lower weight ratio CS, and swelling or tissue damage
from the injection of 180 ratio CS, which will be capable of absorption directly into blood
capillaries at the injection site.
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Figure 2-3. a) Quantification of CpG DNA in LNs after injection of fluorescent-labeled CpG
DNA in soluble or nanoparticle form. b) image showing excised draining LNs from C57BL/6
mice (n=2 LNs per group) injected with fluorescent-labeled CpG DNA (3 nmol) in soluble
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or in nanoparticle form. c) size of inguinal and axillary lymph nodes measured by image J.
d) image showing injection sites of 150, 180, and 300 ratio CS measured two weeks after
injection. e) CpG+ cells determined by flow cytometry at 24 h compared with soluble CpG
DNA. f) representative flow cytometry plots of F4/80 staining and g) CD11c staining.

Given the enhanced delivery of CpG DNA by 150 ratio CS, we examined LN accumulation
again after 30 h using same SiNPs. We questioned ourselves that they may have nonspecific
interaction with serum protein/matrix because of their positively charged surface, and hence
the rate of uptake may slow, compared to negatively charged free CpG DNA. The 150 ratio
SiNPs were injected in C57BL/6 mice, and 30 h later, dLNs were excised (Figure 2-4a).
Nanoparticles showed 1.6-fold greater accumulation in CD11c+ DCs and also in F4/80+
macrophage in inguinal node (Figure 2-4b, c, and d). This results implies that 150 ratio CS
may move slower than negatively charged CpG ODN to reach dLNs. Further studies are
under investigation whether their slower kinetic is beneficial for vaccine delivery.
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Figure 2-4. a) Imaging of excised draining LNs at 30 h from C57BL/6 mice (n=2 LNs per
group) injected with fluorescent-labeled CpG (3 nmol) in soluble or nanoparticle form. b)
CpG+ cells determined by flow cytometry at 24 h. Representative flow cytometry plots of
F4/80 staining and CD11c staining from c) Inguinal node and d) Axillary node.

2.3.3. Design of LN-targeting lipid coated SiNPs and pathogen mimicking composite
materials.
It is well known that PEGylated lipid nanoparticles that can mimic the natural pathogens
enable better retention of encapsulated drugs, and modestly enhance their lymphatic uptake.57
To prepare lipid coated SiNPs, we used a coated lipid film method49 in which nanoparticles
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were added to a continuous lipid film coated onto a round-bottom small tube surface,
allowing uniform coating. This method leads to complete nanoparticle coating, providing
effective vaccine sealing without the necessity to conduct an extrusion or multiple washing
procedures. For LCS fabrication (Figure 2-5a), The 31.5:45:13.5:10 molar ratio of
cholesterol/DOPC/DSPE/mPEG-DSPE in chloroform was dried under nitrogen followed by
incubation under vacuum at room temperature overnight. The resulting lipid films were
resuspended to a concentration of 0.116 g/ml nanoparticles and probe-sonicated for 20 min
with 15/15s on/off working cycle. It has been demonstrated that cholesterol can enhance
transfection efficiency in liposome-based formulations, and PEGylated lipid reduces
nonspecific interactions of vesicles with serum proteins/matrix, enabling better retention of
encapsulated vaccine.58-60 Importantly, the majority of the lipids were found to coat the SiNPs
instead of forming empty liposomes, as rhodamine labeled lipid settled along with the SiNPs
on the bottom of the tube after brief centrifugation (Figure 2-5c). In contrast, sample prepared
without CS showed no sediment layer after centrifugation (Figure 2-5b). We suspected the
positive amines on the surface of SiNPs might interact with lipids and initiate the lipid bilayer
formation.
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Figure 2-5. a) Schematic diagram of LCS and structure of DOPC, DOPE, mPEG-DSPE, and
Cholesterol. b) Image showing rhodamine-conjugated lipid and c) rhodamine-conjugated
lipid with nanoparticles dissolved in saline after centrifugation (21 G for 10 min), the
majority of the lipids settled along with CS nanoparticles.

The surface of LCS was further functionalized with OVA-II peptide that can efficiently
delivery OVA-II antigen and adjuvant to APCs at the same time. An ideal vaccine is one that
is able to mimic the immunological response by a naturally occurring infection. This surface
functionalization makes nanoparticles more “pathogen-mimicking” in respect to their
intracellular fate, persistence and APC activation compared to Yersinia pestis or Escherichia
coli.61 The amphiphilic antigen was anchored on the lipid-coated SiNPs using a post insertion
method.62 We first prepared amph-OVA-II (Figure 2-6a) using a method described
previously63 and added it into LCS solution to prepare OVA-II functionalized LCS (Figure
2-6b). In short, Maleimide-PEG2000-DSPE and OVA-II peptide were dissolved in
Dimethylformamide (DMF) separately, and they were mixed and agitated at room
temperature for 24 hours, following the addition of Triethylamine (TEA) for their coupling
(Figure 2-6a). The prepared amph-OVA-II was added to LCS solution and probe-sonicated
for 1 min with 2/2s on/off working cycle. This nanoparticle will be demonstrated as a
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multifunctional carrier for co-delivery of both OVA-II antigen and CpG ODN adjuvant to
APCs in stimulating antigen-specific CD4+ T cell responses.

Figure 2-6. a) OVA-II peptide with amino-terminal cysteines were conjugated to maleimidePEG2000-DSPE. b) OVA-II functionalized LCS (LCS composite combined with amph-OVAII).

The surface morphology and microstructures of nanoparticles were analyzed using HRTEM. To visualize the lipid bilayer, 2 % phosphotungstic acid (1:1 v/v) was used for negative
staining. Figure 2-7a showed SiNPs with an overall spherical shape and some surface
roughness (black dots). The image of SiNPs without staining showed its smooth surface (no
black dots), implying that black dots were originated from aminosilane functional groups on
the surface of SiNPs (data not shown). The CS image showed no difference in their
morphology compared to bare SiNPs (Figure 2-7b). However, the SiNPs from LCS were
found to be surrounded by a continuous ring of ~ 4 nm distance which is consistent with the
known thickness of a lipid bilayer.64, 65
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Figure 2-7. Transmission electron microscopy (TEM) images of a) SiNPs, b) CS, c) LCS.

2.3.4. Lipid coated SiNPs formulation efficiently targets CpG to the LN.
We prepared fluorescence-labeled LCS (Figure 2-8a) based on the procedure described in
section 2.3.3 to measure their LN accumulation. It showed ~ 110 nm size, which is little
bigger than CS and almost zero surface charge measured by DLS measurements (Figure 28b). The LCS loaded with fluorescently labeled CpG DNA were relatively stable in serum,
releasing only 5 % of the encapsulated CpG DNA when incubated in the presence of 10 %
serum at 37 oC for 3 days (Figure 2-8c). This result implies that nanoparticles were
surrounded by lipid bilayer, enabling better retention of encapsulated CpG DNA. We next
investigated LN accumulation of CpG DNA following subcutaneous injection using a
fluorescence-labeled LCS. Mice treated with LCS showed bigger LNs (Figure 2-8d) and
enhanced lymphatic uptakes compared to results measured by CS administration (Figure 28e). In addition, CpG DNA delivered via LCS platform was detected in approximately 40 %
(2-fold higher than CS) of LN macrophages and DCs from axillary node.
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Figure 2-8. a) Fluorescent images of CS and LCS samples. b) Z-Average and zeta potentials
of CS and LCS measured by DLS c) excised LNs image from C57BL/6 mice (n=2 LNs per
group) injected with CS and LCS. d) size of inguinal and axillary lymph nodes measured by
+

image J. e) CpG cells determined by flow cytometry at 24 h. Representative flow cytometry
plots from cells stained withCD11c and F4/80 f) in inguinal node and g) in axillary node.
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Figure 2-9 showed immunofluorescent images of inguinal LN section. Mice were injected
subcutaneously with 3 nmol of fluorescein-labelled CpG DNA, CS, or LCS. After 24 h, LNs
were sliced by a cryostat and LN cells were stained with antibodies against B220 and CD3.
Histological sections of dLNs showed little detectable CpG DNA, whereas CS and LCS
represented marginally increased CpG DNA accumulation in the subcapsular sinus and
interfollicular areas.

Figure 2-9. Immunohistochemistry of inguinal LNs 24 h after injection (CD3, blue; B220,
pink; CpG, green).
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2.3.5. SiNPs enhances cellular uptake and immune stimulation of CpG in vitro.
The development of ideal vaccines depends on an efficient means of transfer of vaccine
components into a cell. We next studied the effect of our nanoparticle on the transfection
efficiency. For the analysis of confocal laser scanning microscopy, DC2.4 cells were first
seeded on glass coverslips for 24 h at 37 °C and after 24 h, cells were treated with 10 μg/ml
of fluorescence labeled CpG DNA, CS, or LCS for 2 h. Following fixation, the glass was
washed with saline and mounted on a slide with nuclei staining by DAPI. Bright green
fluorescence was observed for cells treated with CS and LCS when excited at 435 nm,
suggesting those nanoparticles could be taken up rapidly by cells (Figure 2-10a). It was also
clearly observed from confocal images that LCS were more closely translocated into the
perinuclear zone. By contrast, the cells that treated with soluble CpG DNA showed only
weak green fluorescence. The kinetics of CpG uptake were quantified by FACS analysis
(Figure 2-10b). Consistent with confocal results, free CpG showed little uptake by DC2.4
cells, in contrast, both LCS and CS nanoparticles had markedly improved uptake, though the
uptake appeared to be more rapid in LCS treated cells. This results suggest that CpG DNA
in nanoparticle form allowed more efficient delivery with minimal leakage into the culture
medium. The SiNPs are known to have a great affinity for the head-groups of a variety of
phospholipids.45 Therefore, the high affinity for adsorbing on cell surfaces may cause
enhanced endocytosis. These observations are consistent with the results of previous studies,
showing that SiNPs are attractive carriers for gene transfection to cells, because the SiNPs
DNA complex has a high transfection efficiency and a low toxicity.45, 66-70
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Figure 2-10. Nanoparticle delivery studied by confocal fluorescence microscopy. a)
Representative confocal microscopy images of DC 2.4 cells. Cell nuclei were stained with
DAPI (blue) and fluorescent-labeled CpG (green) was used to detect CpG uptake. DC 2.4
cells were incubated with adjuvants for 2 h. b) Flow cytometry assay of the uptake. DC 2.4
cells were incubated for 0.5, 1.0, or 2.0 h.

To evaluate the adjuvant activity of nanoparticles, the activation of TLR9 by different CpG
formulations were measured 24 h after incubation. Both Raw-Blue and mTLR9 cells express
TLR9 and are transfected with a secreted embryonic alkaline phosphatase (SEAP) reporter
induced by NF-ĸB. Raw-Blue and mTLR9 cells were incubated with free CpG DNA, CpG
with CS, or CpG with LCS at 37 oC. After 24 hours, 20µL supernatants of cells were
transferred to 200µL Quanti-Blue solution and further incubated for 1 h. The SEAP levels
were determined colorimetrically at 620 nm by UV-Vis. As shown in Figure 2-11, CS and
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LCS stimulated higher level of TLR receptor activation than soluble CpG DNA, which
reflects nanoparticulate CpG modification do not compromise the immunostimulatory
activities of CpG DNA, instead, it enhances the level of stimulation.

Figure 2-11. a) TLR9 cells and b) alkaline phosphatase activity in PBS, CpG DNA, CS, and
LCS, measured from supernatants of cell cultures by Quanti-Blue.

2.3.6. SiNPs formulations trigger potent antigen-specific immune responses.
CpG DNA has been reported to activate cells expressing TLR9 receptor and to promote
expression of costimulatory molecules from APCs that can activate T cell responses.24, 71 To
first measure the impact of nanoparticle delivery on T cell priming, C57BL/6 mice were
immunized subcutaneously on day 0 and day 14 with ovalbumin (OVA) protein alone or
adjuvanted by 1.24 nmol CpG DNA in soluble or in nanoparticle form. The cellular immunity
was monitored by measuring OVA-specific CD8+ T cell proliferation in peripheral blood
using SIINFEKL/H-2Kb peptide-MHC tetramers. As expected, soluble CpG DNA induced
relatively weak antigen-specific CD8+ T cell responses, showing less than 4% OVA-specific
CD8+ T cells in blood. In contrast, LCS elicited 8-fold higher CD8+ T cell proliferation
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(Figure 2-12a and b). Intracellular cytokine staining was also carried out at 7 days after boost
on peripheral blood mononuclear cells restimulated with SIINFEKL peptide to identify
cytokine-producing antigen-specific T cells. LCS-adjuvanted vaccines induced 3-fold and
3.5-fold greater total cytokine+ production in CD8+ and CD4+ T cells, respectively, compared
with vaccination by soluble CpG DNA adjuvant (Figure 2-12a). These results imply that
nanoparticle delivery generate a higher frequency of CD8+ T cells producing both IFN-γ and
TNF-α, which are critical for innate and adaptive immunity against intracellular antigens.72
We further assessed IL-6 and IL-12 production in the sera of immunized mice. Nanoparticle
delivery induced higher IL-6 and IL-12 production compared to vaccination with soluble
CpG DNA (Figure 2-12c). IL-6 has been reported to be involved in the generation of Th2
immune response.73 In contrast, IL-12 production involves multiple signaling pathways in
the production of IFN-γ and TNF-α from T cells and natural killer (NK) cells.22 They mediate
enhancement of the cytotoxic activity of NK cells and CD8+ cytotoxic T lymphocytes.74 Our
result suggests that CpG DNA in nanoparticle form induce a potent immune response through
cell-signaling pathway including MyD88-dependent nuclear factor-κB (NK- κB)75 and
mitogen-activated protein kinase (MAPK)76 pathways, which can induce the secretion of
proinflammatory cytokines such as TNF-α, IL-6, and IL-12.15
Additionally, we evaluated the functional capacity of amphiphilic OVA-II peptide
functionalized LCS elicited T cell response through detection of IFN-γ production following
re-stimulation of peripheral blood mononuclear cells on day 21 with OVA-II peptide (Figure
2-12d and e). The results showed enhanced cytokine production by CD4+ T cell induced by
OVA-II functionalized LCS adjuvanted administration for specific antigen dependent
production of IFN-γ.
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Figure 2-12. Groups of C57BL/6 mice (n=3 per group) were immunized subcutaneously on
day 0 and day 14 with 10 μg OVA and 1.24 nmol CpG DNA, CS, or LCS formulations.
PBMCs were restimulated ex vivo with CD8+ and CD4+ OVA epitopes and analyzed by flow
cytometry for intracellular cytokine staining. a) Mean percentages of OVA specific CD8+ T
cell and TNF-α+ or IFN-γ+ T cell frequencies. b) Representative flow cytometry plots of
OVA-specific CD8+ T cells. c) Levels of IL-6 and IL-12 productions in mice sera detected 3
weeks after immunization. de) IFN-γ+ CD4+ T cell frequencies from each group of C57BL/6
mice (n=3 per group) immunized subcutaneously on day 0 and day 14 with 10 μg AmphOVA-II and 1.24 nmol CpG DNA, CS, or LCS formulations.
.
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We measured the level of OVA-specific IgG in the sera of immunized mice to compare the
capacity for generating humoral immunity. Measurement of the IgG level gives insight into
the types of T helper cell immune responses. It is well known that the immune system
responds to CpG motifs by activating potent Th1-like immune responses.21 To evaluate the
antibody response elicited by soluble CpG DNA or CpG DNA in nanoparticle form, sera
from immunized mice were collected on day 21 following a prime on day 0 and boost on day
14. ELISA measurements of serum titers of OVA-specific IgG showed higher levels of antiOVA IgG in mice immunized by nanoparticle formulations (Figure 2-13a). Mice immunized
by OVA-II functionalized nanoparticles showed significant increases in serum titers against
anti-OVA-II IgG (Figure 2-13b). These nanoparticle-mediated CpG DNA with antigen
delivery enable robust humoral immune responses with higher levels of antigen-specific
antibody productions.
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Figure 2-13. Anti-OVA IgG were measured by ELISA, a) Groups of C57BL/6 mice (n=3 per
group) were immunized subcutaneously on day 0 and day 14 with 10 mg OVA and 1.24 nmol
CpG DNA, CS, and LCS. b) Groups of C57BL/6 mice (n=3 per group) were immunized
subcutaneously on day 0 and day 14 with 10 mg DSPE-PEG-OVA-II and 1.24 nmol CpG
DNA, CS, and LCS.
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2.3.7. SiNPs vaccination elicit a protective anti-tumor immune response.
Several studies have previously shown that in the EG.7-OVA murine lymphoma model,
CpG DNA vaccination resulted in significant regression of tumor growth. 44, 77-82 Therefore,
we next compared the anti-tumor vaccine adjuvant activities of CpG DNA in nanoparticle
form by therapeutically vaccinating C57BL/6 mice bearing OVA-expressing EG.7 thymoma
tumors with no treatment group. A total of 2×106 EG.7-OVA cells were subcutaneously
inoculated into mice. When the tumor mass became palpable (7-8 mm), mice with established
EG.7-OVA tumors were vaccinated on day 5, 11, and 18 with 20 μg OVA plus 1.24 nmol
CpG DNA in nanoparticle form or controls. Nanoparticle delivery containing amph-OVA-II
suppressed tumor growth in the early stage, but differences over the control condition were
lost with time. The CpG DNA in both nanoparticle form plus OVA protein resulted in similar
tumor initiation on day 7 as no treatment group, but delayed tumor growth significantly over
time. The corresponding survival rate also supports the potential utility of our nanoparticle
strategy for prophylactic cancer vaccines (Figure 2-14b). Notably, 2 or 3 mice showed a
drastic inhibition of tumor growth and full recovery from OVA plus CS or OVA plus LCS
group (Figure 2-14c and d). The nanoparticle-adjuvanted vaccine are more effective than
soluble CpG DNA in stimulating tumor-specific cytotoxic T cells responses.
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Figure 2-14. C57BL/6 mice (n=6 per group) were inoculated with 2 × 106 EG.7-OVA cells
s.c. on day 0 and then vaccinated with 20 ug OVA mixed with 1.24 nmol SiNPs based CpG
formulation on days 5, 11, and 18. a) tumor size over time. b) survival over time. c) individual
tumor growth curves. d) An image represents the progression in tumor volume on day 15.

2.4. Conclusion
We used SiNPs as a platform for the efficient delivery of CpG DNA into dLNs for ensuring
their immunostimulatory activity. This approach provides rapid and simple guidelines to
fabricate effective vaccine carriers and understanding how the electrostatic charge interaction
affects their vaccine loading, size, and surface charge. The optimum weight ratio between
SiNPs and CpG DNA was explored, showing their high colloidal stability and efficient CpG
DNA loading with minimal leakage into the medium. For better retention of CpG DNA in
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nanoparticle form (CS), nanoparticles were coated with lipid bilayer, showing their better
stability, enhanced delivery of CpG DNA to lymphatics, and cellular uptake efficiency.
Immunization by nanoparticle delivery generated potent cellular and humoral immunity
superior to vaccination by soluble CpG DNA. Nanoparticle delivery acts synergistically in
suppressing tumor volume, outperforming the delivery of CpG DNA in animal model. Lipid
coated silica nanoparticles revealed in this study can be used as efficient carriers to target
vaccine adjuvants to dLNs, thereby modulating the immune system in safer and effective ways.
We expect that the results of our work will contribute to the advancement of vaccine
encapsulations via charge interactions and will help to develop more efficient therapeutics for
treating cancer.
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3. Dissolving microneedle arrays for transdermal delivery of molecular
vaccines

3.1. Introduction
Delivery of vaccines via the skin is not a new phenomenon. Transdermal delivery through
chemical permeation of the skin has advantages over hypodermic injections, which are
painful, generate dangerous medical waste and spread of disease known to occur through
needle-reuse.

83, 84

Many studies report a connection between unsafe needle-reuse and the

transmission of infectious agents including hepatitis C virus (HCV), hepatitis B virus (HBV),
or human immunodeficiency virus (HIV).85 This needle-based injection also requires
refrigeration that increases costs and complexity of cold transportation (the “cold chain”),
and requires trained health care personnel.86 Meanwhile, transdermal vaccine delivery
systems represent noninvasive, potentially allowing for pain-free administration either by
minimally trained health care providers or through self-administration. This system may
improve safety for the vaccinator by reducing the generation of dangerous medical waste and
inhibiting the spread of disease by needle re-use and needle-based injuries. However,
transdermal vaccine delivery has yet to achieve its potential as an alternative to hypodermic
injections. Perhaps only a limited number of vaccines or difficulties of controlled vaccine
release are major hurdles to practical administration.87 With current delivery systems,
successful transdermal vaccines have molecular masses that are only up to a few hundred
Daltons.83, 88 It has been difficult to deliver hydrophilic vaccines such as DNA or smallinterfering RNA (sRNA) with antigen peptides. Therefore, an optimal approach for safe,
convenient administration of molecular-based adjuvants with antigen peptides through t
he skin remains elusive.
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Here we combined the transdermal vaccine delivery with an ‘albumin hitchhiking’63, 89
approach that uses albumin binding lipids conjugates for the efficient delivery of vaccines
consisting CpG DNA and antigens into dLNs to ensure their immunostimulatory activity. We
first designed microneedle arrays (MNs) composed of a biocompatible polymer (poly(acrylic
acid), PAA), and used them for rapid release of encapsulated vaccine components into
epidermis. The MNs is a glassy hard solid, which has enough strength (Young’s modulus, E
≈ 4 GPa)90 to penetrate the skin and water soluble, facilitating its rapid dissolution when
inserted into skin. To show the utility of this approach, model vaccines composed of peptide
antigen and diacyl lipid-CpG conjugate adjuvants (amph-vaccines) were loaded in MNs and
administered in animal models. Due to the albumin binding nature of amph-vaccines, they
form a complex of appropriate size through binding to albumin, and enhance their efficient
drainage to lymphatics.63 Previous results showed 10-fold higher accumulation in lymph
nodes, 30-fold increases in T cell priming, and enhanced anti-tumor efficacy following
subcutaneous administration.63 In this study, use of MNs platform to deliver amph-vaccines
resulted in enhanced antigen-specific T cell and antibody responses related to traditional
needle-based immunization. This ‘albumin hitchhiking’ MNs delivery system can provide a
simple and safer vaccination method with improved immunogenicity. We hypothesized that
benefits of applying this platform are (i) safe and needle-free administration (no waste of
biological waste and sharp disposal), (ii) no pain and needle phobia, leading to poor patient
compliance, (iii) enhanced immune response through inflammatory cues and targeted
delivery of amph-vaccines to response-governing antigen presenting cells (APCs) present at
high density in the lymph nodes.
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3.2. Background
Our skin consists of three layers such as epidermis, dermis and subcutaneous fat layer. 83,
91, 92

In addition, there is an external physical barrier called the stratum corneum. Methods of

transdermal permeation include hydration, mechanical disruption, and a combination of the
two. It was found that the rate of water loss from skin increased dramatically when the
stratum corneum was removed.88 Hydration of the stratum corneum with inflammatory cue
causes keratinocytes to swell and fluid to pool in the intercellular spaces. This process allows
antigens to pass the skin barrier more easily.93, 94 For such barrier-disruption systems, a si
mple application of MNs can be desired for physical or chemical disruption of the
stratum corneum. Once they penetrate the skin, where immuno-component dendritic
cells are densely distributed, skin permeability could be increased, allowing for trans
dermal delivery of large molecules.95 Ease of administration is also an advantage si
nce rapid and pain-free self-administration of therapeutics into the skin could be app
lied.
Delivery from hypodermal administration results in the compound being deposited either
intramuscularly (IM), subcutaneously (SC), or intradermally (ID). As capable of transporting
nano-sized molecules are available, the larger length scales of needles are often unnecessary,
causing pain and limit targeted delivery. MNs has ~500 μm length, which is enough to
penetrate epidermis. The skin’s pain receptors are located slightly deeper than the length of
MNs so that the delivery using MNs is pain-free in comparison to hypodermic needles. Due
to these property, therapeutics can be delivered precisely into the epidermis without pain or
discomfort.
MNs are specifically designed and developed according to their use and needs.91 Solid
MNs often used to pretreat the skin prior to the administration of therapeutics. It is also used
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to deliver microgram quantities of the substance which may not be suitable for controllable
delivery and could pose disposal or re-use hazards.92 Vaccine-coated and hollow MNs are
used for drug dissolution in the skin. Hollow MNs allows their drug diffuse in deeper later.
Nonetheless, their application is limited as the risk of needle breakage for the injection of
vaccine solutions and also they may leave sharp wastes. Thus, dissolving MNs were
developed as a solution to safety and sharp waste issues. These MNs undergo complete
dissolution in the skin and are typically made of water soluble polymer that dissolve once
exposed to the skin.

3.3. Materials and methods
3.3.1. DNA Synthesis and lipophilic conjugation
All reagents for DNA synthesis were purchased from Chemgenes. G2-CpG (5’GGTCCATGACGTTCCTGACGTT-3’) was first synthesized using an ABI 394 synthesizer
(Applied Biosystems) on a 1.0 micromole scale. Lipophilic phosphoramidite was conjugated
as a final ‘base’ on the 5’ end of G2-CpG (Lipo-G2-CpG63). In this process, lipophilic
phosphoramidite was dissolved in dichloromethane and coupled to G2-CpG using the socalled syringe synthesis technique or using the DNA synthesizer 63. After the synthesis, LipoG2-CpG was cleaved form the solid support by AMA solution (methylamine:acetic
acid=50:50) at 65 oC, and purified by reverse phase high performance liquid chromatography
(HPLC). The schematics of Lipo-G2-CpG is illustrated in Figure 3-1.
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Figure 3-1. Structure of synthesized diacyl lipid conjugated CpG ODN (Lipo-G2-CpG).

3.3.2. Synthesis of peptide amphiphile
Maleimide-polyethylene glycol (PEG)2000-DSPE (Laysan Bio) and OVA-II peptide
(Genescript) were dissolved in Dimethylformamide (DMF) separately. They were mixed
together in the ratio of 2:1 chemical equivalent and small amount of Triethylamine (TEA)
was added for their coupling. The mixture was agitated at 25 oC for 24 hours. The coupling
process and structure of DSPE-PEG2000-OVA-II (amph-OVA-II) are described in Figure 3-2.
The PEG spacer with optimized length between the albumin-binding tail and the OVA-II
antigen was chosen to increase conjugate solubility as well as to promote albumin-binding.

Figure 3-2. OVA-II peptide with amino-terminal cysteines were conjugated to maleimidePEG2000-DSPE.
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3.3.3. Purification of synthesized DNA
Lipo-G2-CpG was purified using reverse phase HPLC (Agilent Technologies 1220 Infinity
LC) on a reverse phase C4 (BioBasic-4, 200 mm × 4.6 mm, Thermo Scientific) column.
The mobile phase consisted of 100 mM trimethylamine-acetic acid buffer (TEAA, pH 7.5)
and methanol (MeOH) as an eluent. The gradient linearity changed from 50:50
(MeOH:TEAA) to 0:100. The total run time was 20 min. The injection volume was 100 μl
and Lipo-G2-CpG was monitored using UV-Vis absorption. Data were collected using
Agilent Rapid Res software.

3.3.4. Design and preparation of MNs
Silicone templates were purchased from Micropoint Technologies Pte Ltd. Templates were
fabricated by casting room temperature vulcanizing silicon over a stainless microneedle
master mold. The template has 10×10 array sharp cavities with 200 μm width and 500 μm
height. They were used to build MNs delivery system through a simple fabrication process
as shown in Figure 3-3a. The dissolving polymer was deposited to the template surface and
centrifuged to compact them into template cavities. Following removal of residual material
from the template surface, templates were dried at room temperature. In this process, vaccine
components remained in not only MNs tips but also MNs body part (pedestal). To avoid this,
the deposition process comprised two stages as shown in Figure 3-3b.
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Figure 3-3. a) Schematic of simple dissolving microneedle fabrication. b) Fabrication of
PAA MNs.

The template was cleaned first by washing with mild soap and letting them air dry
completely, and small amount of PAA-vaccine solution was deposited onto the microneedle
catchment. The PAA (250 kDa, 35 %) was added to soluble OVA and Lipo-G2-CpG mixture
at desired concentrations (generally ~ 40 mg/ml OVA, 32 mg/ml) to prepare the PAA-vaccine
solution. The templates were centrifuged for 20 minutes at rcf ≈ 450 and excess PAAvaccine solution was removed from the template surface for potential reuse. The templates
containing PAA-vaccine were then dried at 25 oC for 24 hours. The PAA pedestals were
formed via addition of 35 % PAA to the template surface, followed by centrifugation (20 min,
rcf ≈ 450), the samples were dried at 25 oC for 48 h, before removing from the template.

3.3.5. Characterization of MNs
MNs were characterized by optical and confocal microscopy using a EVOS AMF4300 and
a Zeiss LSM 510 respectively. The array morphology was further characterized by scanning
electron microscopy (FE-SEM) using a JSM-7600 field effect-SEM and a JSM-6510LV SEM.
Total vaccine loading was determined through brief exposure of fabricated arrays to
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deionized water, followed by an ultraviolet-visible spectroscopy (UV-Vis).

3.3.6. In vivo MNs application and vaccine release
All animal studies were approved by the division of laboratory animal resources (DLAR)
and animals were cared in the DLAR animal facility under federal, state, local, and NIH
guidelines for animal care. The capability of MNs delivery system were tested on
anesthetized C57BL/6 mice at the tail based area. Skin was rinsed briefly with PBS and dried
before application of MNs by gentle pressure. After application, mice were euthanized at
subsequent time points and the application site was dissected. Treated skin and MNs were
imaged by confocal microscopy to assess transcutaneous delivery of PAA-vaccine implants.
For histological analysis, excised skin was embedded in optimal cutting temperature medium
(OCT, Tissue-Tek) and used for sectioning on cryostat (Thermo Fisher HM525 NX).
Histological sections were then imaged using an EVOS AMF4300 imager.

3.3.7. Immunizations
Groups of C57BL/6 mice (n=3 per group) were immunized by ID injection or by MNs
patch (5 min application) on day 0 and day 14 with 10 μg ovalbumin (OVA) including LipoG2-CpG formulations as shown in Figure 3-4a. Groups from 1 to 3 were selected as control
groups to compare immune responses from MNs application with that from ID injections as
shown in Figure 3-4b. Seven days after the final immunization, mice were bled and
peripheral blood mononuclear cells were evaluated by SIINFEKL/H-2Kb peptide-MHC
tetramers staining and intracellular cytokine staining.
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Figure 3-4. a) Mice immunization via ID injection or MNs delivery system (5 min
application), and b) groups of C57BL/6 mice (n = 3 per group).

To assess the functionality of primed CD8+ T cells, peripheral blood mononuclear cells
were stimulated ex vivo with 10 μg/mL OVA peptide SIINFEKL for 6 h with Brefeldin-A and
then fixed, permeabilized, stained with anti-IFN-γ, anti-TNF-α, and anti-CD8α, and analyzed
by flow cytometry. Anti-ovalbumin IgG titers, defined as the dilution of serum at which 450
nm OD will be determined by an enzyme-linked immunosorbent assay (ELISA) analysis. To
determine antibody titers, ELISA plates (eBioscience) were coated with 10 μg/mL of OVA
peptide in PBS 1X overnight at room temperature. The plates were blocked with 200 μL of
1% BSA in PBS (FACS buffer) for 1 h. Serum was serially diluted in PBS 1X between 1:102
and 1:109 and applied to wells for 1 h at room temperature. Peroxidase-conjugated goat antimouse IgG (HþL) (1:5000 in 1% BSA-PBST, 100 μL/well) was then applied for 1 h, and the
plates were developed using TMB substrate (100 μL/well, eBioscience). The reaction was
stopped using 50 μL of 1 M sulfuric acid, 100 μL of the solution and absorbance values were
measured at 450 nm.
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3.3.8. Statistical analysis
To analyze the statistical difference between four groups, a One-Way Analysis of Variance
(ANOVA) with Tukey’s HSD post-hoc test was used. All of the values are expressed as
means ± standard deviations. GraphPad Prism software was used for all the statistical
analyses. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. NS, not significant.

3.4. Results and Discussion
3.4.1. Preparation of MNs
We first designed microneedle geometry and device fabrication process to encapsulate
vaccine components in tips of MNs. To facilitate reliable insertion of MNs into skin, each
was designed to be 500 μm long, which can provide sufficient mechanical strength. To
prepare vaccine loaded MNs, we pursued a double-layered MNs design (Figure 3-3b) using
PAA polymers. First, the PAA solution (250 kDa, 35 %) was mixed with OVA plus TLR9
agonist diacyle lipid conjugated oligo guanine (n=2) repeated CpG DNA (amph-CpG) to
prepare PAA-vaccine solution. Silicone templates were then cast with small amount of PAAvaccine (≈ 5 μl) solution and centrifuged to infiltrate the template cavities. After removing
excess PAA-vaccine solution, templates were allowed to dry at room temperature overnight
to form solid vaccine loaded PAA tips within cavities of templates. Following the dry process,
35 % PAA was added to the template surface and centrifuged to compact the PAA into the
cavities to form PAA pedestal structure. MNs were dried in the template at room temperature
for 48 h (at least 24 h) and removed for future MNs applications (Figure 3-5a).
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Figure 3-5. (a) Face view of dissolving PAA MNs. (b) SEM images of resulting MNs (scale
bar 100 μm) and (c) side view of MNs.

The resulting MNs were reliably produced repeatedly and measured 500 μm tall with sharp
tips as shown in FE-SEM and optical microscope images in Figure 3-5b and c. We further
confirmed this MNs using confocal microcopy to observe the localization of the vaccine
cargo in the tips.

2.4.2. Insertion and dissolution of MNs in skin
The resulting MNs were able to be inserted into murine skin of C57BL/6 mice with gentle
force applied by the thumb (Figure 3-6a and b). To confirm release kinetics of encapsulated
vaccines in MNs, we fabricated rhodamine dye loaded MNs and applied these arrays to the
murine skin for 5 minutes. Confocal imaging on excised skin where patches were applied
represented overlaid punctate fluorescent signal from rhodamine dye at individual sites of
microneedle insertion. It indicates the effective delivery of PAA-loaded vaccine components
upon microneedle penetrations into the cutaneous space (Figure 3-6b). Confocal imaging of
MNs before and after application revealed complete loss of PAA-associated rhodamine dye
signal from the length of each microneedle (Figure 3-6c). We further observed the loss of
tips that were probably dissolved in the skin (Figure 3-6d and e). Upon insertion into murine
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skin, MNs penetrated to a depth of approximately 150 μm and deposited their encapsulated
rhodamine largely within the epidermis (Figure 3-6f).

Figure 3-6. (a) En face view of murine skins after insertion and removal of MNs. (b)
Confocal microscopy image of skins, showing deposition of rhodamine at needle penetration
sites directly following MNs application for 5 min. (c) Confocal microscopy image before
application (upper) and following a 5 min application to murine skin. (d) SEM image and (e)
side views of MNs after applications. (f) Histological structure of mammalian skin after MNs
application.

Together these results confirm MNs can effectively penetrate into murine skin with rapid
dissolution of PAA-vaccine tips upon exposure to skin fluids. Once they penetrate the sk
in, skin permeability could be increased, allowing for targeted delivery of antigen a
nd adjuvant to LNs.
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3.4.3. MNs vaccination
The efficacy of skin immunization with dissolving MNs was determined in C57BL/6 mice
that received encapsulated amph-vaccines. For comparison to parenteral administration, we
performed ID injection of dose-matched OVA plus soluble CpG or amph-CpG formulations
in the murine skin. Mice were immunized on day 0 and boosted on day 14 with 10 μg OVA
plus 1.24 nmol CpG or amph-CpG by ID injection or by MNs administration at the tail base.
The cellular immunity was monitored by measuring OVA-specific CD8+ T cell proliferation
in peripheral blood using SIINFEKL/H-2Kb peptide-MHC tetramers. In view of the results
shown in Figure 3-7, ID injected soluble CpG induced extremely weak antigen-specific CD8+
T cell responses while ID injected amph-CpG elicited stronger CD8+ T cell proliferation.
This amph-CpG promotes binding to albumin in the interstitium and accumulates in antigen
presenting cells in the LNs via albumin trafficking pathways, in turn lead to greatly improved
immune responses as a lymph-directed vaccine carrier.96 Increased access to the lymph and
LNs promotes antigen processing with immune cells compared to free vaccine. MNs
vaccination carrying amph-CpG also showed higher level of CD8+ T cell proliferation,
suggesting MNs delivery provided similar initial immunogenicity compared with traditional
parenteral immunization strategies. We also evaluated the functionality of these expanded T
cells through detection of inflammatory cytokine production following re-stimulation of
peripheral blood mononuclear cells on day 21 ex vivo with SIINFEKL peptide. Flow
cytometric analysis from intracellular staining indicated high frequencies of antigendependent functional cytokine-secreting CD8+ T cells by MNs vaccination. These results
suggest that MNs delivery can generate a higher frequency of CD8+ T cells producing both
IFN-γ and TNF-α, which are critical for innate and adaptive immunity against viral
infections.72
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Figure 3-7. a) Frequency of tetramer+ CD8+ T cells in peripheral blood producing IFN-γ and
TNF-α, and CD4+ T cells producing IFN- γ following SIINFEKL restimulation assessed by
flow cytometry. b) Representative flow cytometric dot plots.

Additionally, we evaluated the functional capacity of lymph node targeting CD4 epitope
(amph-OVA-II) elicited T cell response through detection of IFN-γ production following restimulation of peripheral blood mononuclear cells on day 21 with OVA-II peptide (Figure 38). The results revealed enhanced cytokine production by CD4+ T cell can be induced by
MNs administration of amph-vaccines for specific antigen dependent production of IFN-γ.
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Figure 3-8. Groups of C57BL/6 mice (n=3 per group) were immunized subcutaneously on
day 0 and day 14 with 10 μg amph-OVA-II plus 1.24 nmol CpG or amph-CpG by ID or MNs
vaccination.

Finally, we measured the level of OVA-specific IgG in the sera of immunized mice to compare
the capacity of generating humoral immunity. Measurement of the IgG level gives insight into
the types of T helper cell immune responses. It was reported that the immune system responds
to CpG motifs which is part of CpG ODN by activating potent Th1-like immune responses.21
To evaluate the antibody response elicited by ID or MNs vaccination, we collected sera from
immunized mice on day 21 following a prime on day 0 and boost on day 14 by ID or MNs
vaccination. Here, ELISA measurements of serum titers of OVA-specific IgG showed the
presence of similarly high levels of anti-OVA IgG in mice immunized by ID and MNs
administration of amph-CpG (Figure 3-9a). When animals were immunized by amph-OVA-II
plus amph-CpG formulation, MNs induced significant increases in serum titers for anti-OVA
IgG (Figure 3-9b), similar to amphiphilic vaccines with ID injection.
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Figure 3-9. Anti-OVA IgG were measured by ELISA, a) Groups of C57BL/6 mice (n=3 per
group) were immunized on day 0 and day 14 with 10 μg OVA plus 1.24 nmol CpG or amphCpG by ID or MNs vaccination. b) Groups of C57BL/6 mice (n=3 per group) were
immunized on day 0 and day 14 with 10 μg amph-OVA-II plus 1.24 nmol CpG or amph-CpG
by ID or MNs vaccination.

These increases in the magnitude of cellular immune responses suggest that MNs delivery
can provide systemic dispersion of amph-vaccines released upon skin insertion and plays a
critical role in the adaptive cellular immune response. These results demonstrated the
effectiveness of using MNs as a route for delivering “albumin hitchhiking” vaccines.
Immunization through skin may target vaccine compounds to innate dendritic cells directly
via lymphatic from proximal dLNs in parallel with activating the rich dendritic cell
populations that reside in skin (Figure 3-10). The physical disruption of the epidermal/dermal
tissues during MNs delivery is also considered to be a pivotal role in mediating enhanced
immunity via the recruitment and maturation of APCs.97, 98
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Figure 3-10. Schematic diagram of ‘albumin hitchhiking’ MNs delivery system in relation
to immunology of the skin. The amph-vaccines and antigen internalized dendritic cells traffic
to local lymph nodes to induce an immune response related to T and B cells.
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3.5. Conclusions
We have demonstrated the utility of MNs designed for the systemic dispersion of amphvaccines released upon skin insertion. This approach can provide a number of safety and
immunological advantages compared to hypodermic needles. First, dissolving MNs generate
no biohazardous sharp wastes because the MNs dissolve and disappear upon insertion. The
pedestal part of MNs is also made of water-soluble polymer so that it can easily be eliminated
by dissolving in water. 99 This safety feature removes the risk of accidental needle-stick injury
or intentional reuse of needles, which is common in some developing countries and is
responsible for close to one million deaths per year due to transmission of hepatitis B, HIV
and other infectious diseases.100 Second, the MNs delivery enhances the immune response
through inflammatory cues and targeted delivery of antigen and adjuvant to high density of
APCs in LNs. This approach can greatly increase the safety profile of administered vaccines
by effectively guiding them to dLNs, reducing systemic dissemination.
In conclusion, ‘albumin hitchhiking’ MNs delivery system may provide not only practical
advantages compared to hypodermic needles but also better humoral and cellular immunity.
This strategy can be used as an effective platform for straightforward and robust
transcutaneous vaccine delivery.
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4. Conclusion and future work
We have designed and characterized a system for vaccine delivery that utilizes several
advantages of nanoparticles: surface display of antigen, efficient lymphatic drainage, and
versatile packaging of immunomodulating adjuvants via strong electrostatic surface charge
interactions and T-helper peptides through a membrane post insertion method. We used lipid
coated SiNPs as a platform for the efficient delivery of CpG DNA into dLNs for ensuring their
immunostimulatory activity. This approach showed enhanced delivery of CpG DNA to
lymphatics, and cellular uptake efficiency. Immunization by nanoparticle delivery generated
potent cellular and humoral immunity superior to vaccination by soluble CpG DNA. In addition,
nanoparticle delivery demonstrated improved therapeutic benefits in suppressing tumor growth,
outperforming soluble CpG DNA in animal model. We expect that lipid coated silica
nanoparticles can be used as efficient carriers to target vaccine adjuvants to dLNs, thereby
modulating the immune system in safer and effective ways.
We have also demonstrated the utility of transdermal delivery platforms (microneedle arrays
(MNs)) designed for the systemic dispersion of amph-vaccines released upon skin insertion.
This approach showed a number of safety and immunological advantages compared to
hypodermic needles. MNs delivery enhanced the immune response through inflammatory cues
and targeted delivery of antigen and adjuvant to high density of APCs in LNs. This strategy
can provide not only practical advantages compared to hypodermic needles but also better
humoral and cellular immunity.
Although we observed enhanced efficacy and safety in mice with lipid-coated SiNPs, there
are several important features that have not been addressed in this thesis. For example, the
vaccine kinetics was not fully controlled by our current method. Future studies might focus on
how to maximize the efficacy of adjuvant immunotherapy by controlling the kinetics of
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vaccines exposure in LN. We are currently exploring the possibility of combining nanoparticle
with layer by layer technique to achieve the kinetics control. Additionally, microneedle arrays
might be an ideal approach to facilitate the layer-by-layer delivery of nanoparticles with kinetic
control.
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Adjuvants are immunomodulators which enhance immune responses to vaccines. However,
parenteral administration of unformulated adjuvants fails to reach lymph nodes (LNs), the
anatomic organ where the primary functions of immune cells are orchestrated. The LNtargeting delivery plays the key roles in promoting immune activation and has the great
potential to transform disease treatment. The main goal of this thesis is to develop efficient
vaccine delivery systems to target therapeutics into draining lymph nodes (dLNs) for ensuring
their immunostimulatory activity. We introduced therapeutic applications of activating TLR9
with synthetic CpG oligodeoxynucleotide (ODN) agonists in nanoparticle or molecular form
to activate immune responses in animal models. As a nanoparticle deliver platform, positively
charged silica nanoparticles (SiNPs) were explored to load immunomodulators that are capable
of targeting dLNs and mimicking the size, geometry and surface feathers of live viral pathogens.
Immunization with nanoparticles showed potent cellular and humoral immunity superior to
vaccination with soluble CpG ODNs.
We next explored the transdermal delivery platform using dissolving microneedle arrays
(MNs), which can penetrate the skin and facilitate the rapid release of vaccine components in
epidermis. We combined this strategy with an albumin ‘hitchhiking’ approach that can promote
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interaction with and uptake across the lymphatic endothelium. Vaccination via MNs generated
robust immune responses, showing enhanced T cell and antibody responses. We characterized
the morphology and vaccine loading capabilities of MNs, and systematically explored how the
transdermal delivery of molecular vaccines impacted cellular and humoral immunogenicity.
We expect that the results of our work will contribute to the advancement of vaccine delivery
systems and will help to develop more efficient therapeutics for treating disease or cancer.
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